Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:08:11.717Z.
Calculation as of: 2026-10-06T19:08:11.717Z.
Quote observation: 2026-10-06T19:05:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 08fea6a2878daf509c4a2714b7418dcfec0265989d531cb4479ebc608e1bd708
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$286.29M
EBITDA Yield
N/A
TTM Avg
6.11%
3Y Avg
6.11%
5Y Avg
6.11%
Market Cap
$283.58M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.62M
EBITDA Yield
N/A
TTM Avg
12.31%
3Y Avg
12.19%
5Y Avg
12.19%
Market Cap
$294.92M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.74M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.29M | N/A | 6.11% | 6.11% | 6.11% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.58M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.62M | N/A | 12.31% | 12.19% | 12.19% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $281.81M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $292.16M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.57M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $294.92M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $273.53M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
